Objective: This study compared mothers' report of symptoms of discontinuation syndrome in infants exposed to antidepressants both in utero and during lactation to infants who were exposed only during lactation.
Study Design: This is a convenience sample of 930 women breastfeeding women who answered an online questionnaire about antidepressant use while pregnant and breastfeeding. All 930 women had taken antidepressants while breastfeeding, and 527 had also taken antidepressants during pregnancy. There were no participants in the present study who had taken antidepressants only during pregnancy. The questionnaire was posted on the first author's Medications and Breastfeeding Forum. There was no advertising of this study, nor were efforts made to recruit women into this study beyond posting a notice on the website. The questionnaire included a list of symptoms that mothers may have observed in their infants during the newborn period, as well as demographic questions, and questions about antidepressant use during pregnancy and lactation.
Results: The majority of women reported that their infants never experienced the symptoms of discontinuation syndrome. Twenty-five percent reported infant irritability. A smaller percentage reported inconsolable crying (17%), low body temperature (14%), and significant problems with eating and sleeping (15%). Logistic regression revealed that mothers who took antidepressants while pregnant and then during breastfeeding were two to eight times more likely to report symptoms of discontinuation syndrome than women who took them only while breastfeeding. Discontinuation symptoms were more likely to occur in infants whose mothers took medications with shorter half-lives.
Conclusions: Discontinuation syndrome does occur in a small percentage of infants exposed to antidepressants in utero. Mothers reported a higher frequency of discontinuation syndrome after in utero exposure followed by breastfeeding than when infants were exposed to antidepressants only during lactation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/bfm.2010.0011 | DOI Listing |
Rinsho Shinkeigaku
January 2025
Department of Pediatrics, Hiroshima City Funairi Citizens Hospital.
The patient was a 21-year-old female. She had frequently had status seizures when she had a fever or while taking a bath since she was 6 months old. At 1 year and 8 months old, she developed epilepsy.
View Article and Find Full Text PDFJMIR Form Res
January 2025
Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, United States.
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic syndrome involving urinary frequency, urgency, and bladder discomfort. These IC/BPS symptoms can significantly impact individuals' quality of life, affecting their mental, physical, sexual, and financial well-being. Individuals sometimes rely on peer-to-peer support to understand the disease and find methods of alleviating symptoms.
View Article and Find Full Text PDFJ Pediatr
January 2025
Department of Pediatrics, University of California, San Diego; Rady Children's Hospital, San Diego, CA. Electronic address:
Objective: To describe the clinical course and outcome of 33 patients with Kawasaki disease (KD) treated with cyclosporine (CSA) for coronary artery abnormalities (CAA) or treatment resistance.
Study Design: Single-center, retrospective study of patients with KD treated from 2013 through 2023 for CAA or treatment resistance. Demographics, laboratory studies, medications, adverse events, and echocardiographic data were analyzed.
Medicina (Kaunas)
January 2025
Neurology Department, Cooper University Hospital, Camden, NJ 08103, USA.
: Myoclonus is already associated with a wide variety of drugs and systemic conditions. As new components are discovered, more drugs are suspected of causing this disabling abnormal involuntary movement. This systematic review aims to assess the medications associated with drug-induced myoclonus (DIM).
View Article and Find Full Text PDFRev Med Chil
September 2024
Hospital de Niños Dr. Roberto del Río, Santiago, Chile.
Hereditary tyrosinemia type 1 (HT-1) is an inborn error of metabolism caused by a defect in tyrosine (tyr) degradation. This defect results in the accumulation of succinylacetone (SA), causing liver failure with a high risk of hepatocarcinoma and kidney injury, leading in turn to Fanconi syndrome with urine loss of phosphate and secondary hypophosphatemic rickets (HR). HT-1 diagnosis is usually made in infants with acute or chronic liver failure or by neonatal screening programs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!